CTLA4 and Patent ductus arteriosus: Mono-immunotherapies such as single immune checkpoint inhibitor anti-CTLA4 (ipilimumab), anti-PD1 (nivolumab, pembrolizumab) or anti-PD-L1 (duravalumab) have very limited benefits for PDA patients.